TTRX (TTRX) reported EBIT of -$1.25M in Q1 2026.

How has TTRX's EBIT changed year-over-year?

TTRX's EBIT decreased by 223.7% year-over-year, from -$385K to -$1.25M.

Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.

TTRX TTRX EBIT

EBIT at other companies

Bausch Health CompaniesBHC

-$950M-444%

Journey Medical CorporationDERM

-$1.49M+55.1%

PTH

Pelthos Therapeutics Inc.PTHS

-$13.09M-614%

Celldex TherapeuticsCLDX

-$84.44M-34.6%

Arcutis Biotherapeutics, Inc.ARQT

-$9.09M+62.9%

Regeneron PharmaceuticalsREGN

——

Other financials

Income statement

See full

Operating income-$1.2M-224%

Net income-$971.0K-196%

EPS (diluted)-$0.03-200%

Balance sheet

See full

Cash & equivalents$11.2M+613%

Total debt$6.0M—

Total equity$6.1M+647%

Total assets$18.6M—

Cash flow

See full

Operating cash flow-$1.6M-448%

Valuation

See full

Market cap$217.45M-17.7%

Enterprise value$212.24M—

Returns & leverage

See full

Return on equity-118.8%—

Debt / equity1×—

Current ratio2.2×—

Where this comes from

Calculated from TTRX’s reported figures.

−$1.2Moperating income=-$1.25M

The official record: TTRX’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about TTRX's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is TTRX's EBIT?: TTRX (TTRX) reported EBIT of -$1.25M in Q1 2026.
How has TTRX's EBIT changed year-over-year?: TTRX's EBIT decreased by 223.7% year-over-year, from -$385K to -$1.25M.
What does EBIT mean?: Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.